Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Bioconjugation and Nanomaterials for Clinical Translation
share announcement

Bioconjugation and Nanomaterials for Clinical Translation

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".

Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 15956

Special Issue Editors

Dr. Achraf Noureddine

E-Mail Website
Guest Editor
Department of Chemical and Biological Engineering, University of New Mexico, Albuquerque, NM 87131, USA
Interests: nanomedicine, nanoparticles, cancer, gene delivery, catalysis
Dr. Domenico Marson

E-Mail Website
Guest Editor
Molecular Biology and Nanotechnology Laboratory (MolBNL@UniTS), Department of Engineering and Architecture, University of Trieste, 34127 Trieste, Italy
Interests: molecular dynamic; nanovectors; dendrimers; gene therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The use of nanomaterials to deliver therapeutics has flourished since early 1990s and shown significant advantages over free therapeutic compounds for the treatment of various diseases ranging from hepatitis A and fungal infections to several cancer types and very recently the infectious diseases. Nanomaterials function as nanocarriers by accommodating and protecting the cargo and has thus allowed for the introduction of new therapeutic strategies such as the gene therapy. In addition to the efficacy in disease treatment, other aspects need to be considered to allow for a successful clinical translation such as the pharmacokinetics of the cargo, the nanomaterial’s side-toxicity, its biodistribution and excretion.

This Special Issue serves to highlight the nanomaterials with a clinical translation potential to all types of diseases and the types of nanomaterials that are approved by the international administrations or currently in clinical trials. We invite articles describing nanomaterials capable of undergoing clinical trials to this Special Issue.

Dr. Achraf Noureddine
Dr. Domenico Marson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanomaterials
  • health
  • clinical translation
  • physicochemical properties
  • therapeutic delivery

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

21 pages, 3054 KiB  
Article
Peptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells
by Edison Salas-Huenuleo, Andrea Hernández, Lorena Lobos-González, Iva Polakovičová, Francisco Morales-Zavala, Eyleen Araya, Freddy Celis, Carmen Romero and Marcelo J. Kogan
Pharmaceutics 2022, 14(5), 958; https://doi.org/10.3390/pharmaceutics14050958 - 28 Apr 2022
Viewed by 1588
Abstract
One of the recent attractive therapeutic approaches for cancer treatment is restoring downregulated microRNAs. They play an essential muti-regulatory role in cellular processes such as proliferation, differentiation, survival, apoptosis, cell cycle, angiogenesis, and metastasis, among others. In this study, a gold nanoplatform (GNPF) [...] Read more.
One of the recent attractive therapeutic approaches for cancer treatment is restoring downregulated microRNAs. They play an essential muti-regulatory role in cellular processes such as proliferation, differentiation, survival, apoptosis, cell cycle, angiogenesis, and metastasis, among others. In this study, a gold nanoplatform (GNPF) carrying miR-145, a downregulated microRNA in many cancer types, including epithelial ovarian cancer, was designed and synthesized. For targeting purposes, the GNPF was functionalized with the FSH33 peptide, which provided selectivity for ovarian cancer, and loaded with the miR-145 to obtain the nanosystem GNPF-miR-145. The GNPF-mir-145 was selectively incorporated in A2780 and SKOV3 cells and significantly inhibited cell viability and migration and exhibited proliferative and anchor-independent growth capacities. Moreover, it diminished VEGF release and reduced the spheroid size of ovarian cancer through the damage of cell membranes, thus decreasing cell viability and possibly activating apoptosis. These results provide important advances in developing miR-based therapies using nanoparticles as selective vectors and provide approaches for in vivo evaluation. Full article
(This article belongs to the Special Issue Bioconjugation and Nanomaterials for Clinical Translation)
►▼ Show Figures

Figure 1

20 pages, 8043 KiB  
Article
Light-Decomposable Polymeric Micelles with Hypoxia-Enhanced Phototherapeutic Efficacy for Combating Metastatic Breast Cancer
by Yuanyuan Li, Aiyang Tong, Peiyuan Niu, Wenjing Guo, Yangye Jin, Yi Hu, Pei Tao and Wenjun Miao
Pharmaceutics 2022, 14(2), 253; https://doi.org/10.3390/pharmaceutics14020253 - 21 Jan 2022
Cited by 6 | Viewed by 2865
Abstract
Oxygen dependence and anabatic hypoxia are the major factors responsible for the poor outcome of photodynamic therapy (PDT) against cancer. Combining of PDT and hypoxia-activatable bioreductive therapy has achieved remarkably improved antitumor efficacy compared to single PDT modality. However, controllable release and activation [...] Read more.
Oxygen dependence and anabatic hypoxia are the major factors responsible for the poor outcome of photodynamic therapy (PDT) against cancer. Combining of PDT and hypoxia-activatable bioreductive therapy has achieved remarkably improved antitumor efficacy compared to single PDT modality. However, controllable release and activation of prodrug and safety profiles of nanocarrier are still challenging in the combined PDT/hypoxia-triggered bioreductive therapy. Herein, we developed a near infrared (NIR) light-decomposable nanomicelle, consisting of PEGylated cypate (pCy) and mPEG-polylactic acid (mPEG2k-PLA2k) for controllable delivery of hypoxia-activated bioreductive prodrug (tirapazamine, TPZ) (designated TPZ@pCy), for combating metastatic breast cancer via hypoxia-enhanced phototherapies. TPZ@pCy was prepared by facile nanoprecipitation method, with good colloidal stability, excellent photodynamic and photothermal potency, favorable light-decomposability and subsequent release and activation of TPZ under irradiation. In vitro experiments demonstrated that TPZ@pCy could be quickly internalized by breast cancer cells, leading to remarkable synergistic tumor cell-killing potential. Additionally, metastatic breast tumor-xenografted mice with systematic administration of TPZ@pCy showed notable tumor accumulation, promoting tumor ablation and lung metastasis inhibition with negligible toxicity upon NIR light illumination. Collectively, our study demonstrates that this versatile light-decomposable polymeric micelle with simultaneous delivery of photosensitizer and bioreductive agent could inhibit tumor growth as well as lung metastasis, representing a promising strategy for potent hypoxia-enhanced phototherapies for combating metastatic breast cancer. Full article
(This article belongs to the Special Issue Bioconjugation and Nanomaterials for Clinical Translation)
►▼ Show Figures

Figure 1

16 pages, 48658 KiB  
Article
Endolysosomal Mesoporous Silica Nanoparticle Trafficking along Microtubular Highways
by Achraf Noureddine, Michael L. Paffett, Stefan Franco, Alfonso E. Chan, Sandeep Pallikkuth, Keith Lidke and Rita E. Serda
Pharmaceutics 2022, 14(1), 56; https://doi.org/10.3390/pharmaceutics14010056 - 27 Dec 2021
Cited by 5 | Viewed by 2271
Abstract
This study examines intra- and intercellular trafficking of mesoporous silica nanoparticles along microtubular highways, with an emphasis on intercellular bridges connecting interphase and telophase cells. The study of nanoparticle trafficking within and between cells during all phases of the cell cycle is relevant [...] Read more.
This study examines intra- and intercellular trafficking of mesoporous silica nanoparticles along microtubular highways, with an emphasis on intercellular bridges connecting interphase and telophase cells. The study of nanoparticle trafficking within and between cells during all phases of the cell cycle is relevant to payload destination and dilution, and impacts delivery of therapeutic or diagnostic agents. Super-resolution stochastic optical reconstruction and sub-airy unit image acquisition, the latter combined with Huygens deconvolution microscopy, enable single nanoparticle and microtubule resolution. Combined structural and functional data provide enhanced details on biological processes, with an example of mitotic inheritance during cancer cell trivision. Full article
(This article belongs to the Special Issue Bioconjugation and Nanomaterials for Clinical Translation)
►▼ Show Figures

Figure 1

Review

Jump to: Research

31 pages, 4667 KiB  
Review
Research Progress of Conjugated Nanomedicine for Cancer Treatment
by Bin Zhao, Sa Chen, Ye Hong, Liangliang Jia, Ying Zhou, Xinyu He, Ying Wang, Zhongmin Tian, Zhe Yang and Di Gao
Pharmaceutics 2022, 14(7), 1522; https://doi.org/10.3390/pharmaceutics14071522 - 21 Jul 2022
Cited by 8 | Viewed by 2767
Abstract
The conventional cancer therapeutic modalities include surgery, chemotherapy and radiotherapy. Although immunotherapy and targeted therapy are also widely used in cancer treatment, chemotherapy remains the cornerstone of tumor treatment. With the rapid development of nanotechnology, nanomedicine is believed to be an emerging field [...] Read more.
The conventional cancer therapeutic modalities include surgery, chemotherapy and radiotherapy. Although immunotherapy and targeted therapy are also widely used in cancer treatment, chemotherapy remains the cornerstone of tumor treatment. With the rapid development of nanotechnology, nanomedicine is believed to be an emerging field to further improve the efficacy of chemotherapy. Until now, there are more than 17 kinds of nanomedicine for cancer therapy approved globally. Thereinto, conjugated nanomedicine, as an important type of nanomedicine, can not only possess the targeted delivery of chemotherapeutics with great precision but also achieve controlled drug release to avoid adverse effects. Meanwhile, conjugated nanomedicine provides the platform for combining several different therapeutic approaches (chemotherapy, photothermal therapy, photodynamic therapy, thermodynamic therapy, immunotherapy, etc.) with the purpose of achieving synergistic effects during cancer treatment. Therefore, this review focuses on conjugated nanomedicine and its various applications in synergistic chemotherapy. Additionally, the further perspectives and challenges of the conjugated nanomedicine are also addressed, which clarifies the design direction of a new generation of conjugated nanomedicine and facilitates the translation of them from the bench to the bedside. Full article
(This article belongs to the Special Issue Bioconjugation and Nanomaterials for Clinical Translation)
►▼ Show Figures

Figure 1

28 pages, 13308 KiB  
Review
Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation
by Hanhee Cho, Seong Ik Jeon, Cheol-Hee Ahn, Man Kyu Shim and Kwangmeyung Kim
Pharmaceutics 2022, 14(4), 728; https://doi.org/10.3390/pharmaceutics14040728 - 28 Mar 2022
Cited by 34 | Viewed by 5332
Abstract
Albumin has shown remarkable promise as a natural drug carrier by improving pharmacokinetic (PK) profiles of anticancer drugs for tumor-targeted delivery. The exogenous or endogenous albumin enhances the circulatory half-lives of anticancer drugs and passively target the tumors by the enhanced permeability and [...] Read more.
Albumin has shown remarkable promise as a natural drug carrier by improving pharmacokinetic (PK) profiles of anticancer drugs for tumor-targeted delivery. The exogenous or endogenous albumin enhances the circulatory half-lives of anticancer drugs and passively target the tumors by the enhanced permeability and retention (EPR) effect. Thus, the albumin-based drug delivery leads to a potent antitumor efficacy in various preclinical models, and several candidates have been evaluated clinically. The most successful example is Abraxane, an exogenous human serum albumin (HSA)-bound paclitaxel formulation approved by the FDA and used to treat locally advanced or metastatic tumors. However, additional clinical translation of exogenous albumin formulations has not been approved to date because of their unexpectedly low delivery efficiency, which can increase the risk of systemic toxicity. To overcome these limitations, several prodrugs binding endogenous albumin covalently have been investigated owing to distinct advantages for a safe and more effective drug delivery. In this review, we give account of the different albumin-based drug delivery systems, from laboratory investigations to clinical applications, and their potential challenges, and the outlook for clinical translation is discussed. In addition, recent advances and progress of albumin-binding drugs to move more closely to the clinical settings are outlined. Full article
(This article belongs to the Special Issue Bioconjugation and Nanomaterials for Clinical Translation)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop